BEHRANG AMINI to Proto-Oncogene Proteins c-met
This is a "connection" page, showing publications BEHRANG AMINI has written about Proto-Oncogene Proteins c-met.
Connection Strength
0.146
-
Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. Ann Hematol. 2017 Jun; 96(6):977-985.
Score: 0.117
-
Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion. Oncology. 2016; 91(6):348-353.
Score: 0.029